- Huadong Medicine’s 1Q revenue did not meet the estimated projections.
- The reported revenue was 10.41 billion yuan, which fell short of the estimated 10.91 billion yuan.
- The net income of Huadong Medicine for the quarter was recorded as 862.4 million yuan.
- There were 26 buys and 2 holds for the company’s shares, with no recorded sells.
A look at Huadong Medicine Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Huadong Medicine Co Ltd A is positioned well for long-term growth, with a strong emphasis on expansion and development indicated by its high Growth score of 4. This suggests that the company is actively seeking opportunities to increase its market presence and improve its offerings. Additionally, its above-average Resilience score of 3 highlights that the company is well-prepared to weather any potential challenges or market fluctuations, providing stability to investors.
Furthermore, Huadong Medicine Co Ltd A maintains a balanced outlook across key factors with Value, Dividend, Momentum, and Resilience scores all at a respectable level of 3. This signifies that the company is soundly managed and has the potential for sustainable performance over the long term. In conclusion, with a solid foundation in place across various criteria, Huadong Medicine Co Ltd A appears to be a promising investment opportunity for those looking for steady growth and a reliable presence in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
